Transient metabolic modeling of Escherichia coli MG1655 and MG1655 ΔackA-pta, ΔpoxB Δpppc ppc-p37 for recombinant β-galactosidase production

Mey, Marjan De; Lequeux, Gaspard; Beauprez, Joeri; Maertens, Jo; Waegeman, Hendrik; Bogaert, Inge Van; Foulquié-Moreno, María R.; Charlier, Daniël; Soetaert, Wim; Vanrolleghem, Peter A.; Vandamme, Erick

doi:10.1007/s10295-010-0724-7

Cited by 7 publications

(2 citation statements)

References 39 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also possible to combine different strategies to reduce the formation of undesired by-products, including acetate. For example, one study found that a mutant E. coli strain containing a defective acetate pathway and an overexpressed phosphoenolpyruvate carboxylase-encoding ppC reduced acetate and other by-product formation and produced five time more β-galactosidase activity when compared the wild type strain (De Mey et al, 2010).…”

Section: Efforts In Product Improvements and Generation Of New Analogsmentioning

confidence: 99%

A Review of the Microbial Production of Bioactive Natural Products and Biologics

et al. 2019

View full text Add to dashboard Cite

A variety of organisms, such as bacteria, fungi, and plants, produce secondary metabolites, also known as natural products. Natural products have been a prolific source and an inspiration for numerous medical agents with widely divergent chemical structures and biological activities, including antimicrobial, immunosuppressive, anticancer, and anti-inflammatory activities, many of which have been developed as treatments and have potential therapeutic applications for human diseases. Aside from natural products, the recent development of recombinant DNA technology has sparked the development of a wide array of biopharmaceutical products, such as recombinant proteins, offering significant advances in treating a broad spectrum of medical illnesses and conditions. Herein, we will introduce the structures and diverse biological activities of natural products and recombinant proteins that have been exploited as valuable molecules in medicine, agriculture and insect control. In addition, we will explore past and ongoing efforts along with achievements in the development of robust and promising microorganisms as cell factories to produce biologically active molecules. Furthermore, we will review multi-disciplinary and comprehensive engineering approaches directed at improving yields of microbial production of natural products and proteins and generating novel molecules. Throughout this article, we will suggest ways in which microbial-derived biologically active molecular entities and their analogs could continue to inspire the development of new therapeutic agents in academia and industry.

show abstract

Section: Efforts In Product Improvements and Generation Of New Analogsmentioning

confidence: 99%

A Review of the Microbial Production of Bioactive Natural Products and Biologics

et al. 2019

View full text Add to dashboard Cite

show abstract

“…FK506 is likewise an immunosuppressive medicationas well as it was key exposed in soil trials holding Streptomyces tsukubaensis plus some additional Streptomyces types.FK506 is castoff to minimalize body partrefusal plus to persuade immunosuppression through calcineurin reticence too break of T cell activation pathway .It has established nearer additional actual than cyclosporine plus non poisonous in minute quantities . The detection of its immunosuppressive movement controlled toward its usage in heart, liver, also kidney transplants through irresistible accomplishment .Similar rapamycin, FK506 retains several biological events, as well as antifungal, anti inflammatory, neuron protective, alsoneuron reformative actions [16].…”

Section: Immunosuppressive Agentsmentioning

confidence: 99%

Microfactories-Bioproduction of Chemicals and Pharmaceuticals by using Microbes

Rasool

2021

AJOB

View full text Add to dashboard Cite

A variety of organisms, such as bacteria, fungi, and plants, produce secondary metabolites, also known as natural products. Natural products have been a prolific source and an inspiration for numerous medical agents with widely divergent chemical structures and biological activities, including antimicrobial, immunosuppressive, anticancer, and anti-inflammatory activities, many of which have been developed as treatments and have potential therapeutic applications for human diseases. Aside from natural products, the recent development of recombinant DNA technology has sparked the development of a wide array of biopharmaceutical products, such as recombinant proteins, offering significant advances in treating a broad spectrum of medical illnesses and conditions. Fine chemicals that are physiologically active, such as pharmaceuticals, cosmetics, nutritional supplements, flavoring agents as well as additives for foods, feed, and fertilizer are produced by enzymatically or through microbial fermentation. The identification of enzymes that catalyze the target reaction makes possible to synthesis of the desired fine chemical. The genes encoding these enzymes are then introduced into suitable microbial hosts that are cultured with inexpensive, naturally abundant carbon sources, and other nutrients. Metabolic engineering create efficient microbial cell factories for producing chemicals at higher yields. In the present review, we summarize recent studies on bio-based fine chemical production and assess the potential of synthetic bioengineering for further improvement their productivity.

show abstract

Increasing recombinant protein production in Escherichia coli through metabolic and genetic engineering

Waegeman¹,

Soetaert²

2011

J Ind Microbiol Biotechnol

View full text Add to dashboard Cite

Different hosts have been used for recombinant protein production, ranging from simple bacteria, such as Escherichia coli and Bacillus subtilis, to more advanced eukaryotes as Saccharomyces cerevisiae and Pichia pastoris, to very complex insect and animal cells. All have their advantages and drawbacks and not one seems to be the perfect host for all purposes. In this review we compare the characteristics of all hosts used in commercial applications of recombinant protein production, both in the area of biopharmaceuticals and industrial enzymes. Although the bacterium E. coli remains a very often used organism, several drawbacks limit its possibility to be the first-choice host. Furthermore, we show what E. coli strains are typically used in high cell density cultivations and compare their genetic and physiological differences. In addition, we summarize the research efforts that have been done to improve yields of heterologous protein in E. coli, to reduce acetate formation, to secrete the recombinant protein into the periplasm or extracellular milieu, and to perform post-translational modifications. We conclude that great progress has been made in the incorporation of eukaryotic features into E. coli, which might allow the bacterium to regain its first-choice status, on the condition that these research efforts continue to gain momentum.

show abstract

Transient metabolic modeling of Escherichia coli MG1655 and MG1655 ΔackA-pta, ΔpoxB Δpppc ppc-p37 for recombinant β-galactosidase production

Cited by 7 publications

References 39 publications

A Review of the Microbial Production of Bioactive Natural Products and Biologics

A Review of the Microbial Production of Bioactive Natural Products and Biologics

Microfactories-Bioproduction of Chemicals and Pharmaceuticals by using Microbes

Increasing recombinant protein production in Escherichia coli through metabolic and genetic engineering

Contact Info

Product

Resources

About